These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31027700)

  • 1. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
    Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant
    Tobiášová K; Barthová M; Janáková Ľ; Lešková K; Farkašová A; Loderer D; Grendár M; Plank L
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125737
    [No Abstract]   [Full Text] [Related]  

  • 5. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
    Lee Y; Cho Y; Park EY; Park SY; Hwang KH; Han JY
    Oncologist; 2021 Oct; 26(10):e1683-e1692. PubMed ID: 34272914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer.
    Park CK; Kim JE; Kim MS; Kho BG; Park HY; Kim TO; Shin HJ; Cho HJ; Choi YD; Oh IJ; Kim YC
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2071-2082. PubMed ID: 31154543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.
    Volckmar AL; Endris V; Bozorgmehr F; Lier C; Porcel C; Kirchner M; Leichsenring J; Penzel R; Thomas M; Schirmacher P; Warth A; Stenzinger A
    Diagn Pathol; 2016 Nov; 11(1):133. PubMed ID: 27863497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Cell-Free DNA for the Detection of
    McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
    Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
    [No Abstract]   [Full Text] [Related]  

  • 10. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
    Conde E; Suárez-Gauthier A; Benito A; Garrido P; García-Campelo R; Biscuola M; Paz-Ares L; Hardisson D; de Castro J; Camacho MC; Rodriguez-Abreu D; Abdulkader I; Ramirez J; Reguart N; Salido M; Pijuán L; Arriola E; Sanz J; Folgueras V; Villanueva N; Gómez-Román J; Hidalgo M; López-Ríos F
    PLoS One; 2014; 9(9):e107200. PubMed ID: 25248157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
    Letovanec I; Finn S; Zygoura P; Smyth P; Soltermann A; Bubendorf L; Speel EJ; Marchetti A; Nonaka D; Monkhorst K; Hager H; Martorell M; Sejda A; Cheney R; Hernandez-Losa J; Verbeken E; Weder W; Savic S; Di Lorito A; Navarro A; Felip E; Warth A; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dienemann H; Dziadziuszko R; Vansteenkiste J; O'Brien C; Geiger T; Sherlock J; Schageman J; Dafni U; Kammler R; Kerr K; Thunnissen E; Stahel R; Peters S;
    J Thorac Oncol; 2018 Mar; 13(3):413-425. PubMed ID: 29191776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.
    Xia J; Chen S; Zhang Z; Wang J
    Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study.
    Mok T; Peters S; Camidge DR; Noé J; Gadgeel S; Ignatius Ou SH; Kim DW; Konopa K; Pozzi E; Liu T; Loftin IR; Williams C; Shaw AT
    J Thorac Oncol; 2020 Oct; ():. PubMed ID: 34756882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.
    Li W; Wan R; Guo L; Chang G; Jiang D; Meng L; Ying J
    BMC Med; 2022 May; 20(1):160. PubMed ID: 35534835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
    Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
    Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.
    Le Quesne J; Maurya M; Yancheva SG; O'Brien M; Popat S; Wotherspoon AC; de Castro DG; Nicholson AG
    J Thorac Oncol; 2014 Jun; 9(6):769-74. PubMed ID: 24787965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of EML4-ALK Fusion V1 Subtype Lung Adenocarcinoma 
Detected by RNA-based NGS].
    Xu Y; Mu N; Liu M; Wu S; Ma C
    Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):480-484. PubMed ID: 39026500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
    Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
    Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of two-step approach for screening NTRK fusion in two major subtypes of non-small cell lung cancer within a large cohort.
    Dong K; Zhu Y; Liu X; Sun W; Yang X; Chi K; Jia L; Diao X; Huang X; Zhou L; Lin D
    Hum Pathol; 2024 Jul; 149():39-47. PubMed ID: 38866255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.
    Rao W; Liu Y; Li Y; Guo L; Qiu T; Dong L; Ying J; Li W
    Front Med; 2023 Jun; 17(3):493-502. PubMed ID: 37010729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.